dc.contributor.author | Karaçin, Cengiz | |
dc.contributor.author | Karaçin, Pınar | |
dc.contributor.author | Ergün, Yakup | |
dc.date.accessioned | 2022-07-28T07:43:08Z | |
dc.date.available | 2022-07-28T07:43:08Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Karacin, C., Karacin, P., & Ergun, Y. (2021). Tamoxifen in breast cancer survivors with COVID 19: stop or go?. Medical oncology (Northwood, London, England), 38(4), 42. https://doi.org/10.1007/s12032-021-01492-z | en_US |
dc.identifier.issn | 1357-0560 | |
dc.identifier.issn | 1559-131X | |
dc.identifier.uri | https://doi.org/10.1007/s12032-021-01492-z | |
dc.identifier.uri | https://hdl.handle.net/11436/6279 | |
dc.description.abstract | The COVID 19 pandemic threatens human health in many
ways. Although vaccines that have completed phase 3 trials
are being used today, it is estimated that the risk of infection will continue for a while | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.title | Tamoxifen in breast cancer survivors with COVID 19: stop or go? | en_US |
dc.type | letter | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Karaçin, Cengiz | |
dc.contributor.institutionauthor | Karaçin, Pınar | |
dc.identifier.doi | 10.1007/s12032-021-01492-z | en_US |
dc.identifier.volume | 38 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 42 | en_US |
dc.relation.journal | Medical Oncology | en_US |
dc.relation.publicationcategory | Diğer | en_US |